Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of four medications commonly used together in general anesthesia protocols: - **Cisatracurium besylate**: A non-depolarizing neuromuscular blocking agent (NMBA) with intermediate onset and duration of action. It is one of ten isomers of atracurium besylate (constituting approximately 15% of that mixture) and functions by blocking neuromuscular transmission at cholinergic receptors. It facilitates endotracheal intubation and provides skeletal muscle relaxation during surgery or mechanical ventilation. - **Propofol**: An intravenous anesthetic agent used for induction and maintenance of general anesthesia. - **Remifentanil**: A potent, short-acting synthetic opioid analgesic used during general anesthesia for pain control. - **Sevoflurane**: An inhalational anesthetic agent used for induction and maintenance of general anesthesia. This combination provides complete general anesthesia with hypnosis (propofol, sevoflurane), analgesia (remifentanil), and muscle relaxation (cisatracurium).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cisatracurium besylate + propofol + remifentanil + sevoflurane.